Evopoint Biosciences has submitted its IPO guidance application to the China Securities Regulatory Commission (CSRC), with Guotai Haitong Securities serving as the advising institution. The clinical-stage biotech focuses on oncology, antibiotic-resistant infections and metabolic diseases through multiple technology platforms including targeted therapies and antibody-drug conjugates.

Its most advanced candidate, BLI inhibitor XNW4107 for carbapenem-resistant bacterial infections, has completed Phase III trials and is in pre-filing stage. The company has secured multiple global licensing deals and completed Series A through E financings, including a RMB 700 million Series E round in 2024 led by Tencent and Xin Capital.